Literature DB >> 2087873

Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.

J L Stanford1, G A Rook, G M Bahr, Y Dowlati, R Ganapati, K Ghazi Saidi, S Lucas, G Ramu, P Torres, H Minh Ly.   

Abstract

Both leprosy and tuberculosis present continuing problems in their control, especially in the developing world, despite the availability of drugs effective in producing a bacteriological cure. Improved immunoprophylaxis, and an effective immunotherapy to be used with chemotherapy are urgently required. Intradermal injection of a suspension of killed Mycobacterium vaccae promotes cell-mediated responses to antigens common to all mycobacteria, and switches off the tissue-necrotizing aspects of the Koch phenomenon. These properties led to the use of the suspensions as an improved vaccine, either alone or in combination with BCG. The same properties led to the employment of the suspension in immunotherapy as an adjunct to chemotherapy in the treatment of both leprosy and tuberculosis. The evidence leading to these conclusions is reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2087873     DOI: 10.1016/0264-410x(90)90002-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

Review 2.  MULTIDRUG RESISTANT TUBERCULOSIS - BIOMECHANISM, EPIDEMIOLOGY AND MANAGEMENT STRATEGIES.

Authors:  S C Tewari; S P Kalra; S Dangwal; R S Chatterji
Journal:  Med J Armed Forces India       Date:  2017-06-26

3.  Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae.

Authors:  C Abou-Zeid; M P Gares; J Inwald; R Janssen; Y Zhang; D B Young; C Hetzel; J R Lamb; S L Baldwin; I M Orme; V Yeremeev; B V Nikonenko; A S Apt
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

4.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

5.  Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy.

Authors:  P J Converse; A M Dannenberg; T Shigenaga; D N McMurray; S W Phalen; J L Stanford; G A Rook; T Koru-Sengul; H Abbey; J E Estep; M L Pitt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

6.  Recognition of a common mycobacterial T-cell epitope in MPB59 of Mycobacterium bovis.

Authors:  K A Lightbody; R M Girvin; D A Pollock; D P Mackie; S D Neill; J M Pollock
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

7.  Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.

Authors:  Xiao-Yan Yang; Qun-Fei Chen; You-Ping Li; Si-Miao Wu
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

Review 8.  Tuberculosis vaccines: beyond bacille Calmette-Guerin.

Authors:  Helen McShane
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 9.  Dogma and innovation in the global control of tuberculosis: discussion paper.

Authors:  J M Grange; J L Stanford
Journal:  J R Soc Med       Date:  1994-05       Impact factor: 18.000

Review 10.  Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.

Authors:  Sam Afkhami; Anne Drumond Villela; Michael R D'Agostino; Mangalakumari Jeyanathan; Amy Gillgrass; Zhou Xing
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.